Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low‐dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition. (17th April 2013)

• Record Type: Journal Article
• Authors: Wu, C.; Zhang, H.; Qian, Y.; Wang, L.; Gu, X.; Dai, Z.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 38:Number 4(2013:Aug.)
• Page Start: 321
• Page End: 326
• Publication Date: 2013-04-17
• Subjects: Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12050
• Languages: English
• ISSNs: 0269-4727

Abstract

<abstract abstract-type="main" xml:lang="en" id="jcpt12050-abs-0001"> <title>Summary</title> <sec id="jcpt12050-sec-0001" sec-type="section"> <title>What is known and Objective</title> <p>Adefovir dipivoxil (ADV) is one of the commonly used antiviral agents in the treatment of chronic hepatitis B (CHB) infection. Safety of a daily dose of 10 mg ADV is advocated by the registration trials. We report a case of severe hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low‐dose ADV in a CHB‐related cirrhosis patient, and discuss the case through a thorough review of other cases reported in the literature.</p> </sec> <sec id="jcpt12050-sec-0002" sec-type="section"> <title>Case summary</title> <p>A 48‐yr‐old Chinese man with CHB‐related cirrhosis developed severe progressive generalized bone pain and muscle weakness after receiving ADV 10 mg daily for 54 months. The laboratory results showed severe hypophosphatemia and features of proximal renal tubule dysfunction. Imaging studies were consistent with osteomalacia. After discontinuation of ADV, his symptoms resolved, laboratory abnormalities normalized and imaging studies showed improvement. In addition to our case, 12 other patients have been reported to have developed hypophosphatemic osteomalacia induced by low‐dose ADV. Most of the reported cases were of subjects of East‐Asian ethnicity. After discontinuation or reduction of ADV, serum phosphate level increased and clinical symptoms significantly improved in all cases.</p> </sec> <sec id="jcpt12050-sec-0003" sec-type="section"> <title>What is new and Conclusion</title> <p>Hypophosphatemic osteomalacia and renal Fanconi syndrome can be associated with low‐dose ADV. Clinicians treating CHB patients with ADV 10 mg daily over long periods of time should be aware of this infrequent but serious complication</p> </sec> </abstract>